Raymond James & Associates’s Acceleron Pharma Inc. XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-11,314
| Closed | -$1.95M | – | 4156 |
|
|
2021
Q3 | $1.95M | Sell |
11,314
-1,153
| -9% | -$198K | ﹤0.01% | 2120 |
|
|
2021
Q2 | $1.56M | Sell |
12,467
-1,509
| -11% | -$189K | ﹤0.01% | 2275 |
|
|
2021
Q1 | $1.9M | Buy |
13,976
+1,549
| +12% | +$210K | ﹤0.01% | 2050 |
|
|
2020
Q4 | $1.59M | Buy |
12,427
+1,574
| +15% | +$201K | ﹤0.01% | 2033 |
|
|
2020
Q3 | $1.22M | Buy |
10,853
+22
| +0.2% | +$2.48K | ﹤0.01% | 2055 |
|
|
2020
Q2 | $1.03M | Buy |
10,831
+4,038
| +59% | +$385K | ﹤0.01% | 2136 |
|
|
2020
Q1 | $610K | Sell |
6,793
-599
| -8% | -$53.8K | ﹤0.01% | 2283 |
|
|
2019
Q4 | $392K | Buy |
7,392
+17
| +0.2% | +$902 | ﹤0.01% | 2895 |
|
|
2019
Q3 | $291K | Sell |
7,375
-80
| -1% | -$3.16K | ﹤0.01% | 3009 |
|
|
2019
Q2 | $306K | Sell |
7,455
-1,843
| -20% | -$75.6K | ﹤0.01% | 2985 |
|
|
2019
Q1 | $433K | Buy |
9,298
+90
| +1% | +$4.19K | ﹤0.01% | 2749 |
|
|
2018
Q4 | $401K | Sell |
9,208
-147
| -2% | -$6.4K | ﹤0.01% | 2687 |
|
|
2018
Q3 | $535K | Sell |
9,355
-151
| -2% | -$8.64K | ﹤0.01% | 2652 |
|
|
2018
Q2 | $461K | Buy |
9,506
+28
| +0.3% | +$1.36K | ﹤0.01% | 2735 |
|
|
2018
Q1 | $371K | Buy |
9,478
+164
| +2% | +$6.42K | ﹤0.01% | 2746 |
|
|
2017
Q4 | $395K | Buy |
9,314
+728
| +8% | +$30.9K | ﹤0.01% | 2665 |
|
|
2017
Q3 | $320K | Sell |
8,586
-14
| -0.2% | -$522 | ﹤0.01% | 2735 |
|
|
2017
Q2 | $261K | Buy |
8,600
+1,017
| +13% | +$30.9K | ﹤0.01% | 2797 |
|
|
2017
Q1 | $201K | Buy |
+7,583
| New | +$201K | ﹤0.01% | 2911 |
|